Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
Adani Power shares bounce back, rise 6% after 2-day selloff. What triggered the surge ?
25/09/2025
Dixon Technologies shares rise as UBS upgrades it to buy rating, sees 27% upside
25/09/2025
Citi re-initiates coverage on SBI with ‘buy’ rating, sets Rs 1,050 target price
25/09/2025
Gold prices take a breather, but hold firm above Rs 1.12 lakh/10 gms. Time to book gains or ride the trend ?
25/09/2025
Big EV market reset under way ? China's BYD smokes Tesla again, leaves Musk in dust for 2nd time in 2 months in EU
25/09/2025
US equities end lower as valuation concerns creep in
25/09/2025
